CD19 CAR T-cell Therapy in Infant B-ALL: Durable Remissions, Relapse Patterns, and Molecular Correlates

Key Points

• Durable remissions were achieved following CD19 CAR T-cell therapy in infants with B-ALL, indicating treatment effectiveness.
• The study reported a 70% remission rate at the six-month mark for infants receiving the therapy, confirming its potential.
• Assessment involved observing relapse patterns and molecular correlates in patients with B-ALL post-therapy across multiple centers.
• These findings highlight the importance of targeted therapies in infant leukemia, though more research is needed to understand long-term implications.